Skip to main content

Clementia Pharma May Be A Fit For Investors Looking For Undervalued Biotech Names

By: via Benzinga
Wedbush initiated coverage of Clementia Pharmaceuticals Inc (NASDAQ: CMTA) at Outperform and a $26 price target. The firm believes ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.